Mamta V Manglani1, Yashwant R Gabhale2, Mamatha M Lala1, Rohini Sekhar1, Dipti More1. 1. Pediatric Centre of Excellence for HIV Care (PCoE), Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India. 2. Pediatric Centre of Excellence for HIV Care (PCoE), Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, India. Correspondence to: Dr. Yashwant R. Gabhale, Deputy Program Director, Pediatric Centre of Excellence for HIV Care (PCoE), Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai-22, India. dryashg@rediffmail.com.
Abstract
OBJECTIVE: To determine the prevalence of HLA-B*5701 allele in HIV-infected children, and to find its association with Abacavir hypersensitivity. METHODS: Children (2 to 18 y) already on, or to be initiated on Abacavir were included for PCR sequencing to detect HLA-B*5701. OUTCOME MEASURES WERE: proportion with HLA B*5701 allele and hypersensitivity with Abacavir. Abacavir was stopped if patient tested positive for HLA-B*5701 allele. RESULTS: 100 children (median age 11 y) were enrolled; 10 were already on Abacavir. HLA-B*5701 positivity was observed in 11 (11%) children. Two of these 11 children developed hypersensitivity after initiation of Abacavir. Abacavir was thereafter stopped in all who tested HLA-B*5701 positive, irrespective of the development of hypersensitivity reaction. CONCLUSION: HLA-B*5701 allele was present in 11 (11%) of HIV-infected children, of which two developed Abacavir hypersensitivity. None of the patients without the allele developed hypersensitivity.
OBJECTIVE: To determine the prevalence of HLA-B*5701 allele in HIV-infectedchildren, and to find its association with Abacavirhypersensitivity. METHODS:Children (2 to 18 y) already on, or to be initiated on Abacavir were included for PCR sequencing to detect HLA-B*5701. OUTCOME MEASURES WERE: proportion with HLA B*5701 allele and hypersensitivity with Abacavir. Abacavir was stopped if patient tested positive for HLA-B*5701 allele. RESULTS: 100 children (median age 11 y) were enrolled; 10 were already on Abacavir. HLA-B*5701 positivity was observed in 11 (11%) children. Two of these 11 children developed hypersensitivity after initiation of Abacavir. Abacavir was thereafter stopped in all who tested HLA-B*5701 positive, irrespective of the development of hypersensitivity reaction. CONCLUSION:HLA-B*5701 allele was present in 11 (11%) of HIV-infectedchildren, of which two developed Abacavirhypersensitivity. None of the patients without the allele developed hypersensitivity.
Authors: Julie Jesson; Laura Saint-Lary; Marc Harris Dassi Tchoupa Revegue; John O'Rourke; Claire L Townsend; Françoise Renaud; Martina Penazzato; Valériane Leroy Journal: Lancet Child Adolesc Health Date: 2022-09-02